Literature DB >> 30815391

Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2019        PMID： 30815391      PMCID： PMC6388565          DOI： 10.1159/000496277

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  17 in total

1.  Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-10-26       Impact factor: 11.740

2.  Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents.

Authors:  Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

3.  Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma.

Authors:  Naoshi Nishida
Journal:  Hepatobiliary Surg Nutr       Date:  2020-10       Impact factor: 7.293

4.  Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-07-09       Impact factor: 11.740

5.  A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-03-05       Impact factor: 11.740

6.  A six-miRNA signature as a novel biomarker for improving prediction of prognosis and patterns of immune infiltration in hepatocellular carcinoma.

Authors:  Zhitao Chen; Lele Zhang; Chenchen Ding; Kuiwu Ren; Dalong Wan; Shengzhang Lin
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

7.  Effect of Hematocrit Injury on the Survival Rate of Advanced Malignant Tumors and Its Clinical Significance.

Authors:  Lin Li; Weibin Wu; Mingdi Yin
Journal:  Comput Math Methods Med       Date:  2022-06-15       Impact factor: 2.809

Review 8.  Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Authors:  Ti Zhang; Philippe Merle; Huaqi Wang; Haitao Zhao; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265

Review 9.  Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2020-04-27       Impact factor: 6.639

Review 10.  Tumor microenvironment complexity and therapeutic implications at a glance.

Authors:  Roghayyeh Baghban; Leila Roshangar; Rana Jahanban-Esfahlan; Khaled Seidi; Abbas Ebrahimi-Kalan; Mehdi Jaymand; Saeed Kolahian; Tahereh Javaheri; Peyman Zare
Journal:  Cell Commun Signal       Date:  2020-04-07       Impact factor: 5.712
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.